< Back to search
Filter
1
New

A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

for
Locally Advanced or Metastatic Solid Tumors
Location: Lake Success NY, Fairfax VA
Sponsor: Astellas Pharma Global Development, Inc.

Sex: All

Age: 18+

Code: NCT07730021

Phase1, Phase2, Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

for
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion,
Location: South Portland ME, Boston MA, New Haven CT, New York NY,
Sponsor: Bayer

Sex: All

Age: 0+

Code: NCT04142437

Recruiting

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

for
Advanced or Metastatic Solid Tumor
Location: Lake Success NY, East Brunswick NJ, Fairfax VA,
Sponsor: Pliant Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06270706

Phase1, Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

for
Advanced or Metastatic Solid Tumors, Breast Cancer,
Location: Boston MA, New Haven CT, New York NY, Philadelphia PA,
Sponsor: 858 Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06395519

Phase1, Phase2, Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

for
Advanced or Metastatic Solid Tumors
Location: New Haven CT, New York NY, Toronto, Sarasota FL,
Sponsor: Day One Biopharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT06752681

Phase1, Recruiting

Interested in new advanced solid tumor trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

for
Advanced or Metastatic Solid Tumor Malignancies
Location: Bethesda MD
Sponsor: GigaGen, Inc.

Sex: All

Age: 18+

Code: NCT06258304

Phase1, Recruiting

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

for
Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer,
Location: Boston MA, New Haven CT, Fairfax VA, Nashville TN,
Sponsor: Incendia Therapeutics

Sex: All

Age: 18+

Code: NCT05753722

Phase1, Recruiting

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

for
Locally Advanced or Metastatic Solid Tumors
Location: Margate FL, San Antonio TX, Beverly Hills CA
Sponsor: Pyrotech Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06244992

Phase1, Phase2, Recruiting

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

for
Advanced or Metastatic Solid Tumor, Liver Failure
Location: Newark DE, Baltimore MD, Houston TX, San Antonio TX
Sponsor: Gilead Sciences

Sex: All

Age: 18+

Code: NCT04617522

Phase1, Recruiting

Study of XB010 in Subjects With Solid Tumors

for
Locally Advanced or Metastatic Solid Tumors,
Location: The Bronx NY, Washington D.C. DC, Fairfax VA,
Sponsor: Exelixis

Sex: All

Age: 18+

Code: NCT06545331

Phase1, Recruiting

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

for
Advanced or Metastatic Solid Tumors
Location: New Haven CT, Philadelphia PA, Baltimore MD, Fairfax VA,
Sponsor: Takeda

Sex: All

Age: 18+

Code: NCT07205718

Phase1, Phase2, Recruiting

A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

for
Advanced NRAS-Mutant Melanoma,
Location: Boston MA, New York NY, Fairfax VA, Grand Rapids MI,
Sponsor: Relay Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07584226

Phase1, Recruiting

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

for
Advanced or Metastatic Solid Tumors
Location: Boston MA
Sponsor: Hanmi Pharmaceutical Company Limited

Sex: All

Age: 18+

Code: NCT06724016

Phase1, Recruiting

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

for
Advanced or Metastatic Solid Tumors,
Location: San Antonio TX, Scottsdale AZ
Sponsor: SHY Therapeutics

Sex: All

Age: 18+

Code: NCT07705334

Phase1, Recruiting

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

for
KRAS Altered Advanced or Metastatic Solid Tumors
Location: Boston MA, Montreal, Philadelphia PA, Fairfax VA,
Sponsor: Amgen

Sex: All

Age: 18+

Code: NCT07094113

Phase1, Recruiting

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

for
Advanced or Metastatic Solid Tumors
Location: New Haven CT, The Bronx NY, Baltimore MD, Miami FL,
Sponsor: DynamiCure Biotechnology

Sex: All

Age: 18+

Code: NCT05785754

Phase1, Recruiting

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

for
Advanced or Metastatic Solid Tumors
Location: Tampa FL, Cincinnati OH, Grand Rapids MI,
Sponsor: Hanmi Pharmaceutical Company Limited

Sex: All

Age: 18+

Code: NCT06234397

Phase1, Recruiting

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

for
Solid Tumors
Location: Philadelphia PA, Gainesville FL, Houston TX
Sponsor: Shionogi

Sex: All

Age: 18+

Code: NCT05101070

Phase1, Phase2, Recruiting

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

for
Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer,
Location: Boston MA, New York NY, Madison WI, Aurora CO,
Sponsor: I-Mab Biopharma US Limited

Sex: All

Age: 18+

Code: NCT04900818

Phase1, Recruiting

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

for
Solid Tumor, MET Alteration
Location: Washington D.C. DC, Canton OH, Nashville TN
Sponsor: Pierre Fabre Medicament

Sex: All

Age: 18+

Code: NCT06669117

Phase1, Phase2, Recruiting